New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress
<i>Background and objectives</i>: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fib...
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
MDPI AG
2022-04-01
|
| Reeks: | Medicina |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/1648-9144/58/4/530 |
| Samenvatting: | <i>Background and objectives</i>: COVID-19 is associated with an aberrant inflammatory response that may trigger new-onset cardiac arrhythmias. The aim of this study was to assess the mortality risk in hospitalized COVID-19 patients according to IL-6 serum levels and new-onset atrial fibrillation (AF) according to PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Materials and Methods</i>: 175 COVID-19 patients (25 new-onset AF, 22 other types of AF and 128 no-AF) were included in this single-center, retrospective study; clinical and demographic data, vital signs, electrocardiograms and laboratory results were collected and analyzed. The primary outcome of the study was to evaluate the mortality rate in new-onset AF patients according to IL-6 serum levels and PaO<sup>2</sup>/FiO<sup>2</sup> stratification. <i>Results:</i> The incidence of new-onset AF in the study population was 14.2%. Compared to the no-AF group, new-onset AF patients were older with a positive history of chronic kidney disease and heart failure, had higher IL-6, creatinine and urea serum levels whereas their platelet count was reduced. After PaO<sup>2</sup>/FiO<sup>2</sup> stratification, 5-days mortality rate was higher in new-onset AF patients compared to patients with other types of AF and no-AF patients, and mortality risk increases 5.3 fold compared to no-AF (<i>p</i> = 0.0014) and 4.8 fold compared to other forms of AF (<i>p</i> = 0.03). <i>Conclusions:</i> New-onset AF is common in COVID-19 patients and is associated with increased IL-6 serum levels and early mortality. Further studies are needed to support the use of IL-6 as an early molecular target for COVID-19 patients to reduce their high rate of mortality. |
|---|---|
| ISSN: | 1010-660X 1648-9144 |